Furthermore, to investigate the potential improvement in the efficacy of compound 17 through CD36 inhibition, primary CRC cells from Pt 93 and Pt 130 were subjected to treatment with the CD36 inhibitor sulfosuccinimidyl oleate and the FASN inhibitor compound 17. This evidence concerns the gene FASN and colorectal carcinoma.